Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry

E. Sebastian Debus; Victor Aboyans; Jackie Bosch; Keith A.A. Fox; Manesh R. Patel; Robert C. Welsh; Uwe Zeymer; Ala Gay; Kai Vogtländer; Sonia S. Anand

doi:10.1016/j.ejvs.2024.07.017

July 1, 2024European Journal of Vascular and Endovascular SurgeryOpen Access

Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

To assess the characteristics and clinical outcomes of patients with lower extremity peripheral artery disease (PAD) in XATOA receiving dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin according to lower extremity revascularisation (LER) history.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Debus et al. (2024) studied this question.

synapsesocial.com/papers/68e61f3fb6db6435875b0f97 https://doi.org/10.1016/j.ejvs.2024.07.017

View Full Paper

Ask AI

Bookmark

Share

Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry

Ask about this paper

Abstract

Discussion

Cite This Study

Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading